Whole Versus Partial Gland Boost During Prostate SBRT

Starting soon · Phase 2/Phase 3

Conditions studied: Prostate Cancer, Prostate Adenocarcinoma

In brief

This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.

Key facts

Study ID

NCT07574489

Run by

University of Nebraska

People needed

186

Starts

2026-07-25

Expected to finish

2035-08-25

Last updated by the study team

2026-06-29

Who can join

Age: 19 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥19 years of age
• Patients with a diagnosis of prostate adenocarcinoma for which stereotactic body radiotherapy (SBRT) to the prostate ± proximal seminal vesicles is being offered
• Prostate gland volume <100 cc prior to initiation of androgen deprivation therapy (ADT), as reported at time of biopsy or by imaging (e.g., ultrasound, MRI, or CT)
• PI-RADS 4 or 5 lesion seen on pre-treatment MRI
• IPSS/AUA symptom score less than 16

You may not qualify if…

• Prior treatment for prostate cancer
• Prior solid cancer diagnosis within the last 5 years
• Any history of anal or rectal cancer
• Any history of invasive carcinoma of the bladder
• History of prior circumferential resection of the rectum (such as LAR or APR)

Where it is running

• Fred & Pamela Buffet Cancer Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.